U.S. Stock Market Movement | Omvoh Phase III Trial for Pediatric Ulcerative Colitis Successful, Eli Lilly (LLY.US) Surges Over 5%, Reaches Record High

智通财经APP reported that on Tuesday, Eli Lilly (LLY.US) rose over 5% to $1,309.39, reaching a new all-time high. According to reports, on October 19, Eli Lilly announced that the Phase 3 SHINE-2 study of Omvoh for the treatment of pediatric ulcerative colitis achieved its primary endpoint; among 52 patients aged 6 to 17 who exhibited a clinical response to Omvoh, 50% achieved clinical remission by week 52. Omvoh has already been approved in the United States for the treatment of active ulcerative colitis and Crohn's disease in adults. The company plans to submit the study results to global regulatory agencies and seek to expand the drug's indications.